The investigators want to develop a gene expression profile the for prediction the chemotherapeutic response of patients with metastatic breast cancer.
1. Metastatic breast cancer tissue is obtained from core needle biopsies pretreatment and is flash frozen and stored at -70℃ until processing. 2. After patients received docetaxel combination thiotepa for two cycles, response is assessed using Response Evaluation Criteria in Solid Tumor Group (RECIST) guidelines. Degree of response is used to divide the cancers into two groups-sensitive and resistant tumours. 3. The gene expression in metastatic breast cancer tissue sample is detected by microarray to screen gene markers that are differently expressed between groups 4. Statistical analysis is performed using unsupervised hierarchical cluster.
Study Type
OBSERVATIONAL
Enrollment
42
Beijing Cancer Hospital
Beijing, China
Chemotherapy response
Response to chemotherapy is assessed using Response Evaluation Criteria in Solid Tumor Group (RECIST) guidelines
Time frame: four-months
Time to disease progression
Time to disease progression is measured from the date therapy is initiated to the date of documented disease progression.
Time frame: six months
Overall survival
Overall survival is measured from the date therapy is initiated to the date of death or final follow-up.
Time frame: one year
clinical benefit response
clinical benefit response include CR,PR,SD
Time frame: six months to one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.